WOODBRIDGE, ON, Oct. 30, 2013 /CNW/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies
for cardiovascular disease (CVD) and overall health, announced today
that John P. Nicholson Jr., MD, MBA, FACC has been appointed to the
Company's Board of Directors.
Dr. Nicholson is a Cardiologist and Clinical Associate Professor of
Medicine at Cornell University. He is currently the Medical Director of
the Cardiac Health Center, cardiac rehabilitation program at New York
Hospital - Queens. Dr. Nicholson has over thirty years of experience as
a healthcare and life sciences investor, analyst and portfolio manager.
He was the founder and Portfolio Manager of Sands Point Partners. Dr.
Nicholson's previous roles on Wall Street include healthcare Portfolio
Manager at Steinhardt Partners, consultant at Tiger Management, and
Director of Healthcare Investment Banking at the Bank Street Group. Dr.
Nicholson is also the Chairman of privately held Tivorsan
Pharmaceuticals and the Director of Research at Crossover Healthcare
"We are pleased to welcome Dr. Nicholson to the Board of Directors of
Pivotal Therapeutics. Dr. Nicholson's medical and investment expertise
make him an exceptional addition to the Board at this stage of the
Company's development. We look forward to his input as a leading edge
Cardiologist as we continue to study the clinical effects of VASCAZEN® in cardiac rehabilitation, obesity, metabolic syndrome and heart
failure" said Dr. George Jackowski, Co-founder and Chairman of
Pivotal's Board of Directors. "Dr. Nicholson is a recognized leader in
clinical medicine and this combined with his extensive investment
experience and unique perspective is why we believe Dr. Nicholson will
make a significant contribution to the Board as we explore various
strategic initiatives with VASCAZEN® and enter into our next stage of growth as a company" said Dr. George
"As a Cardiologist we see numerous drugs that aim to treat
cardiovascular diseases and symptoms of underlying cardiovascular
disease. I am excited that a company is exploring Omega-3 deficiency,
its affects and addressing Omega-3 deficiency in a novel way, through
utilization of a Medical Food that corrects the underlying deficiency
itself. Pivotal's approach is interesting and innovative and I look
forward to serving on its Board of Directors," said Dr. Nicholson.
VASCAZEN® is currently available in the U.S. as a prescription only Medical Food
specifically formulated for the dietary management of an Omega-3
deficiency in cardiovascular patients. VASCAZEN® is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid
formulation, protected by a series of both U.S. and foreign patents.
VASCAZEN® has been clinically shown to correct an Omega-3 deficiency within eight
weeks of treatment with positive concomitant effects on the lipid
profiles, mainly a 48% reduction of triglycerides and an increase of
HDL without negative impact on the LDL-C lipid profile. VASCAZEN®'s results were achieved with a dose of 3 grams of EPA and DHA per day
of a prescription grade, high purity Omega-3.
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CNSX: PVO)
specialty pharmaceutical company with a focus on cardiovascular disease
and overall health. Pivotal Therapeutics' lead product VASCAZEN® is a prescription only Medical Food formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease through
elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular complications. OMAZENTM is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in
each capsule for the maintenance of good health. OMAZENTM is a patented product available for sale and distribution in Canada.
The information contained in this document is as of October 30, 2013.
This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal's actual results
to differ materially from those projected in such forward-looking
statements. These statements can be identified by the use of words such
as "will", "anticipate", "estimate", "expect", "project", "forecast",
"intend", "plan", "believe", "project", "potential", and similar
expressions with any discussion of future operating or financial
performance or events. In particular, factors that could cause actual
results to differ materially from those in forward looking statements
include the following: Pivotal's inability to obtain additional
financing on acceptable terms; growth in costs and expenses; inability
to compete with others who provide comparable products; risk that the
Company's products will not gain widespread market acceptance; risks
relating to the Company's ability to maintain its CSNX listing.
Forward-looking statements speak only as of the date made and are not
guarantees of future performance. The Company undertakes no obligation
to publicly update or revise any forward-looking statements contained
in this document as a result of new information or future events or
developments. CNSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this information.
SOURCE: Pivotal Therapeutics Inc.
For further information:
President and Chief Operating Officer
Communications and Public Relations Manager
Phone: 905-856-9797 ext. 231